GSK announces positive results from phase III severe asthma trials …
May 21, 2024 · Depemokimab is the first ultra-long-acting biologic to be evaluated in phase III trials with a binding affinity and high potency for interleukin-5 (IL-5), enabling six-month dosing …
Twice-Yearly Depemokimab in Severe Asthma with an …
Sep 9, 2024 · Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals.
Depemokimab, the first ultra-long-acting anti-IL-5 monoclonal
Dec 13, 2024 · Depemokimab, the first ultra-long-acting anti-IL-5 monoclonal antibody, significantly reduced exacerbation rates in patients with severe eosinophilic asthma when …
Depemokimab Every 6 Months Reduces Rate of Severe Asthma …
Jan 3, 2025 · A recent study found that depemokimab (GSK3511294; GSK) was successful in reducing the annualized rate of exacerbations in patients with severe asthma with an …
Depemokimab, the first ultra-long-acting anti-IL-5 monoclonal …
Dec 13, 2024 · Depemokimab (GSK3511294) is a new humanized, affinity-matured IgG 1 mAb that blocks interleukin-5 (IL-5), a key cytokine involved in eosinophil maturation, survival, and …
Twice-Yearly Biologic Cuts Severe Asthma Exacerbation Rate in Half
Sep 9, 2024 · Depemokimab, an anti-IL-5 neutralizing antibody, was engineered to have enhanced IL-5 binding affinity and potency, potentially enabling every 6-month dosing.
Depemokimab, the first ultra-long-acting anti-IL-5 monoclonal …
Dec 13, 2024 · Depemokimab, the first ultra-long-acting anti-IL-5 monoclonal antibody, significantly reduced exacerbation rates in patients with severe eosinophilic asthma when …
Depemokimab a twice yearly injection for severe asthma
Dec 22, 2024 · Depemokimab, a novel ultra long-acting anti-IL-5 monoclonal antibody, has emerged as a promising treatment option. This review examines the efficacy, safety, and …
Phase III Trials Show Depemokimab Reduces Severe Asthma …
Jun 12, 2024 · Positive results from the phase III SWIFT-1 and SWIFT-2 trials with depemokimab demonstrated that, compared with placebo, the interleukin- (IL) 5 inhibitor significantly reduced …
Depemokimab in Severe Asthma | New England Journal of Medicine
Dec 18, 2024 · Depemokimab, an ultra-long-acting biologic agent with enhanced binding affinity for interleukin-5, may improve outcomes in patients with asthma with an eosinophilic phenotype.